Role of multi-biomarkers and algorithms for diagnosis of early-stage ovarian cancer
DOI:
https://doi.org/10.18203/2320-1770.ijrcog20233665Keywords:
Diagnosis of ovarian cancer, Biomarkers, Ultrasonography algorithmsAbstract
Our reviews intend to provide a comprehensive update for the diagnosis of ovarian cancer using biomarkers (CA125) and ultrasonography algorithm RMI and ROMA and how to improve our approaches to identify and diagnose ovarian cancer in early stage and improve the survival rate This meta-analysis done in the Department of Obstetrics and Gynaecology Swaroop Rani hospital Prayagraj, Uttar Pradesh. Source of literature was all the standard online articles available in last 3years and also the departmental records of the last 1year following criteria CA125, HE4, RMI, ROMA for screening or diagnosis. Our result on the basis of ODDS ratio and confidence interval (CI) of tumour marker like CA125, HE4, RMI, ROMA from different study. Overall estimation and pooled estimation determined by forest plot and our pooled estimation is present between the 0.8 OR to 1.0 OR and 95 % of confidence interval of the result. Our study concludes that RMI has comparatively good OR ratio and pooled effect of forest plot is in favour of RMI 0.8 OR to 1.0 OR and had good opportunity to identify early-stage ovarian cancer. Our study concludes that RMI score has comparatively good OR ratio and it can be used to identify early-stage ovarian cancer which can help in on time intervention and improved outcomes in such patients.
References
Atallah GA, Abd Aziz NH, Teik CK, Shafiee MN, Kampan NC. New Predictive Biomarkers for Ovarian Cancer. Diagnostics. 2021;11(3):465.
Ovary Cancer. Available at:httpps#//seer.cancer.gov/ stattacts/html/ovary.html;surveillance epidemiology and end results program. Accessed on 20 February 2023.
Muinao T, Deka Boruah HP, Pal M. Multi-biomarker panel signature as the key to diagnosis of ovarian cancer. Heliyon. 2019;5(12):e02826.
Quirk JT, Natarajan N. Ovarian cancer incidence in the United States, 1992-1999. Gynecol Oncol. 2005;97(2): 519-23.
Sölétormos G, Duffy MJ, Othman Abu Hassan S, Verheijen RH, Tholander B, et al. Clinical Use of Cancer Biomarkers in Epithelial Ovarian Cancer: Updated Guidelines From the European Group on Tumor Markers. Int J Gynecol Cancer. 2016;26(1):43-51.
Chen YS, Yang WL, Zhao YL, Yang YG. Dynamic transcriptomic m5 C and its regulatory role in RNA processing. Wiley Interdiscip Rev RNA. 2021; 12(4):e1639.
Ferraro S, Braga F, Lanzoni M, Boracchi P, Biganzoli EM, Panteghini M. Serum human epididymis protein 4 vs carbohydrate antigen 125 for ovarian cancer diagnosis: a systematic review. J Clin Pathol. 2013; 66(4):273-81.
Drapkin R, von Horsten HH, Lin Y, Mok SC, Crum CP, Welch WR, et al. Human epididymis protein 4 (HE4) is a secreted glycoprotein that is overexpressed by serous and endometrioid ovarian carcinomas. Cancer Res. 2005;65:2162-9.
Moore RG, Brown AK, Miller MC. The use of multiple novel tumor biomarkers for the detection of ovarian carcinoma in patients with a pelvic mass. Gynecol Oncol. 2008;108(2):402-8.
Dodge JE, Covens AL, Lacchetti C, Elit LM, Le T, Devries-Aboud M, Fung-Kee-Fung M, et al. Preoperative identification of a suspicious adnexal mass: a systematic review and meta-analysis. Gynecol Oncol. 2012;126(1):157-66.
Chen PJ, Pusica Y, Sohaei D, Prassas I, Diamandis EP. An overview of mental health during the COVID-19 pandemic. Diagnosis (Berl). 2021;8(4):403-12.
Yurkovetsky Z, Skates S, Lomakin A, Nolen B, Pulsipher T, Modugno F, et al. Development of a multimarker assay for early detection of ovarian cancer. J Clin Oncol. 2010;28(13):2159-66.
Kim YW, Bae SM, Lim H, Kim YJ, Ahn WS. Development of multiplexed bead-based immune assays for the detection of early stage ovarian cancer using a combination of serum biomarkers. PLoS One. 2012;7(9):e44960.
Pal MK, Rashid M, Bisht M. Multiplexed magnetic nanoparticle-antibody conjugates (MNPs-ABS) based prognostic detection of ovarian cancer biomarkers, CA-125, β-2M and ApoA1 using fluorescence spectroscopy with comparison of surface plasmon resonance (SPR) analysis. Biosens. Bioelectron. 2015; 73:146-52.
Nolen B, Velikokhatnaya L, Marrangoni A, De Geest K, Lomakin A, Bast RC, et al. Ovarian Cancer. Gynecol Oncol. 2010;117(3):440-5.
Visintin I, Feng Z, Longton G, Ward DC, Alvero AB, Lai Y, et al. Diagnostic markers for early detection of ovarian cancer. Clin Cancer Res. 2008;14(4):1065-72.
Jacobs I, Oram D, Fairbanks J, Turner J, Frost C, Grudzinskas JG. A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer. Br J Obstet Gynaecol. 1990;97(10): 922-9.
Tanha K, Mottaghi A, Nojomi M, Moradi M, Rajabzadeh R, Lotfi S, et al. Investigation on factors associated with ovarian cancer: an umbrella review of systematic review and meta-analyses. J Ovarian Res. 2021;14(1):153.
Pal T, Permuth-Wey J, Kumar A, Sellers TA. Systematic review and meta-analysis of ovarian cancers: estimation of microsatellite-high frequency and characterization of mismatch repair deficient tumor histology. Clin Cancer Res. 2008;14(21):6847-54.
Wang J, Gao J, Yao H, Wu Z, Wang M, Qi J. Diagnostic accuracy of serum HE4, CA125 and ROMA in patients with ovarian cancer: a meta-analysis. Tumour Biol. 2014;35(6):6127-38.
Suri A, Perumal V, Ammalli P, Suryan V, Bansal SK. Diagnostic measures comparison for ovarian malignancy risk in Epithelial ovarian cancer patients: a meta-analysis. Sci Rep. 2021;11(1):17308.
Hernández JF, Escudero DL, Méndez LIP, Quintana DRB, Santana Eb, Álvarez JAP, et al. Evaluation of the incorporation of an IOTA-ADNEX model in the discrimination of adnexal masses in our third-level hospital centre, taking into account the menopausal status of patients. Clín Investigate Ginecol Obstet. 2023;51(1):1016.
Cui R, Wang Y, Li Y, Li Y. Clinical value of ROMA index in diagnosis of ovarian cancer: meta-analysis. Cancer Manag Res. 2019;11:2545-51.
